Baxalta announces U.S. availability of ADYNOVATE, a new treatment for hemophilia A
Baxalta announced the launch and first shipments of ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated], an extended circulating half-life recombinant factor VIII treatment for hemophilia A based on full-length ADVATE [Antihemophilic Factor (Recombinant)]. November 30, 2015